Sign up USA
Proactive Investors - Run By Investors For Investors

M Pharma to remove parabens from new acquisition's products

The company will use an exclusive license it is acquiring for a new paraben-free technology for the task.
picture of lipstick
Parabens have been used in cosmetic and pharmaceutical products since the fifties

M Pharmaceutical Inc (CNSX:MQ) is to strip all parabens from 40Js' products once it completes its acquisition.

The company will use an exclusive license it is acquiring for a new paraben-free technology for the task.

Parabens have been used in cosmetic and pharmaceutical products since the fifties to improve shelf life and prevent bacteria.

 “There is a growing concern with parabens, as they have been shown to disrupt hormone function, an effect that is linked to an increased risk of certain cancers and reproductive issues,” said Gary Thompson, M Pharma's chief executive.

They were banned in the EU in 2012, but are still used in the US.

 “We are taking a two phase approach to maximizing this new proprietary technology for replacing parabens,” said Thompson.

“Phase one will be to formulate all M Pharmaceutical products to include this new parabens free technology. This will be implemented immediately following the closing of the 40J’s acquisition.

The second phase will be to out-license the parabens-free technology to other manufacturers. 

M Pharma agreed to acquire Cincinnati-based 40Js at the start of January and is currently going through the due diligence process.

 

PhilW.jpg
Why Invest In M Pharmaceutical? Read More Here

Register here to be notified of future MQ Company articles
View full MQ profile

M Pharmaceutical Timeline

Related Articles

Knee.jpg
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.
Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.
brokerreport.jpg
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use